Abstract
The management of elderly diabetic patients has become a real public health problem due to the increase in the number of patients. In this population, the complications of diabetes are more serious and are associated with manifestations more specifically gerontological. The standardized geriatric assessment is essential to define the situation of each patient according to his degree of autonomy and undernutrition, his cognitive functions, and his social environment. The therapeutic objectives must be individualized according to the clinical status of the patient. Insulin therapy is often unavoidable and requires a good education of the patient or his family. The management of diabetes in elderly patients must also avoid too much laxity in a person who is remained healthy but also unreasonable activism in the fragile subjects due to the hypoglycemic risk.
References
Institut national de la statistique et des études économiques.
Ricci P, Blotière P.O, Weill A, Simon D, Tuppin P, Ricordeau P,et al. Diabète traité : quelles évolutions entre 2000 et 2009 en France. BEH. 2010;N°42- 43:425-31. [Accessed 22 Jun 2021]. Available from : https://www.santepubliquefrance.fr/maladies-et-traumatismes/diabete/documents/article/diabete-traite-quelles-evolutions-entre-2000-et-2009-en-france
Bauduceau B, Berrut G, Blickle JF, Brocker P, Constant T, BourdelMarchasson I, et al.Guide pour la prise en charge du diabétique âgé. Méd mals Métabol. 2008 ;2 :Hors-série 1. [Accessed 22 Jun 2021]. Available from: https://www.sfdiabete.org/sites/www.sfdiabete.org/files/files/ressources/mmm_2008_guide_diabetique_age.pdf
Sinclair A, Morley JE, Rodriguez-Mañas L, Paolisso G, Bayer T, Zeyfang A, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes.J Am Med Dir Assoc. 2012 Jul ;13(6):497-502. https://doi.org/10.1016/j.jamda.2012.04.012
Munshi MN, Florez H, Huang ES, Kalyani RR, Mupanomunda M, Pandya N, et al. Management of Diabetes in Long-term Care and Skilled Nursing Facilities: A Position Statemen of the American Diabetes Association. Diabetes Care. 2016 Feb; 39(2):308-18. https://doi.org/10.2337/dc15-2512
American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2016; 39: 1:S1-S110.
Doucet J, Le Floch JP, Bauduceau B, Verny C, SFD/SFGG Intergroup. GERODIAB: Glycaemic control and 5-year morbidity/mortality of type 2 diabetic patients aged 70 years and older: 1. Description of the population at inclusion. Diabetes Metab. 2012 Dec; 38(6):523-30. https://doi.org/10.1016/j.diabet.2012.07.001
Bourdel-Marchasson I, Helmer C, Fagot-Campagna A, Dehail P, Joseph PA. Disability and quality of life in elderly people with diabetes. Diabetes Metab. 2007 Apr; 33 Suppl 1:S66-74. https://doi.org/10.1016/s1262-3636(07)80058-9
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. https://doi.org/10.1093/gerona/56.3.m146
Comment repérer la fragilité en soins ambulatoires. HAS. 2013 Jun. [Cited 22 Jun 2021]. Available From: https://www.has-sante.fr/jcms/c_1602970/fr/comment-reperer-la-fragilite-en-soins-ambulatoires
Massin P, Kaloustian E. The elderly diabetic's eyes. Diabetes Metab. 2007 Apr; 33 Suppl 1:S4-9. https://doi.org/10.1016/s1262-3636(07)80052-8
Pataky Z, Vischer U. Diabetic foot disease in the elderly. Diabetes Metab. 2007Apr; 33 Suppl 1:S56-65. https://doi.org/10.1016/s1262-3636(07)80057-7
Chanudet X, Bonnevie L, Bauduceau B. Coronary heart disease and cardiovascular autonomic neuropathy in the elderly diabetic. Diabetes Metab. 2007 Apr;33Suppl 1:S19-31. https://doi.org/10.1016/s1262-3636(07)80054-1
Bauduceau B, Bordier L, Chanudet X. Une complication mal connue du diabète : la cardiomyopathie diabétique. Méd Mal Metab. 2011 Dec; 5:605-9. https://doi.org/10.1016/S1957-2557(11)70326-1
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26; 373(22):2117-28. https://doi.org/10.1056/nejmoa1504720
Bauduceau B, Doucet J, Le Floch JP, Verny C, SFD/SFGG Intergroup and the GERODIAB Group. Cardiovascular events and geriatric scale scores in elderly (70 years old and above) type 2 diabetic patients at inclusion in the GERODIAB cohort. Diabetes Care. 2014;37(1):304-11. https://doi.org/10.2337/dc13-1540
Vischer UM, Bauduceau B, Bourdel-Marchasson I, Blickle JF, Constans T, Fagot-Campagna A, et al. A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly. Diabetes Metab. 2009 Jun; 35(3):168- 77. https://doi.org/10.1016/j.diabet.2009.02.003
Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies. Diabetologia. 2005 Dec; 48(12):2460-9. https://doi.org/10.1007/s00125-005-0023-4
Verny C, Doucet J, Constans T, Bauduceau B, Le Floch JP the SFD / SFGG Intergroup. Prevalence of Cognitive Decline and Associated Factors in Elderly Type 2 Diabetic Patients at Inclusion in the GERODIAB Cohort. European Geriatric Medicine. 2015 Feb; 6(1):36- 40. https://doi.org/10.1016/j.eurger.2014.10.006
Schrijvers EM, Witteman JC, Sijbrands EJ, Hofman A, Koudstaal PJ, Breteler MM. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology. 2010 Nov 30; 75:1982-7. https://doi.org/10.1212/wnl.0b013e3181ffe4f6
Yaffe K, Falvey CM, Hamilton N, Harris TB, Simonsick EM, Strotmeyer ES, Et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013 Jul 22;173(14):1300-6. https://doi.org/10.1001/jamainternmed.2013.6176
Stratégie de prise en charge en cas de dénutrition protéino-énergétique chez la personne âgée. HAS. Jun 2007. [Accessed 22 Jun 2021]. Available From :https://www.has-sante.fr/jcms/c_5465 49/ fr/strategie-de-prise-en-charge-en-cas-de-denutrition-proteino-energetique-chez-la-personne-agee
Bordier L, Buysschaert M, Bauduceau B, Doucet J, Verny C, Lassmann Vague V, et al. Predicting factors of hypoglycaemia in elderly type 2 diabetes patients: Contributions of the GERODIAB study. Diabetes Metab. 2015 Sep;41(4):301-3. https://doi.org/10.1016/j.diabet.2015.03.001
Recommandations de la Société Française d'Hypertension Artérielle. Prise en charge de l'hypertension artérielle de l'adulte. HAS. Oct 2016. . [Accessed 22 Jun 2021]. Available From: https://www.has-sante.fr/jcms/c_2059286/fr/prise-en-charge-de-l-hypertension-arterielle-de-l-adulte
Bouhanick B, Meliani S, Doucet J, Bauduceau B, Verny C, Chamontin B, et al. Orthostatic hypotension is associated with more severe hypertension in elderly autonomous diabetic patients from the French Gerodiab study at inclusion. Ann CardiolAngeiol. 2014 Jun;63(3):176-82. https://doi.org/10.1016/j.ancard.2014.05.013
French Society of Endocrinology (SFE), Francophone Society of Diabetes (SFD),New French Society of Atherosclerosis (NSFA), Béliard S, Bonnet F, Bouhanick B, Et al. Consensus statement on the management of dyslipidaemias in adults.Diabetes Metab. 2016 Dec; 42(6):398-408. https://doi.org/10.1016/j.diabet.2016.07.033
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015 Jan; 38(1):140 -9. https://doi.org/10.2337/dc14-2441
Recommandation de bonne pratique. Stratégie médicamenteuse du contrôle glycémique du diabète de type 2. HAS. Jan 2013. [Accessed 22 Jun 2021]. Available From :https://www.has-sante.fr/upload/docs/application/pdf/2013-02/10irp04_reco_diabete_type_2.pdf
Bouillet B, Vaillant G, Petit JM, Duclos M, Poussier A, Brindisi MC, et al. Are elderly patients with diabetes being overtreated in French long-term-care homes? Diabetes Metab. 2010 Sep;36(4):272-7. https://doi.org/10.1016/j.diabet.2010.01.009
Pornet C, Bourdel-Marchasson I, Lecomte P, Eschwège E, Romon I, Fosse S, et al; ENTRED Scientific Committee. Trends in the quality of care for elderly people with type 2 diabetes: the need for improvements in safety and quality (the 2001 and 2007 ENTRED Surveys). Diabetes Metab. 2011; 37(2):152-61. https://doi.org/10.1016/j.diabet.2011.02.001
Hall KS, Morey MC, Dutta C, Manini TM, Weltman AL, Nelson ME, et al. Activity-related energy expenditure in older adults: a call for more research. Med Sci Sports Exerc. 2014 Dec; 46(12):2335-40. https://doi.org/10.1249/mss.0000000000000356
Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, et al. Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010 Nov;170(21):1892-9. https://doi.org/10.1001/archinternmed.2010.409
Eriksson JW, Bodegard J, Nathanson D, Thuresson M, Nyström T, Norhammar A. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract. 2016 Jul; 117:39-47. https://doi.org/10.1016/j.diabres.2016.04.055
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369 :1317-26. https://doi.org/10.1056/nejmoa1307684
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes .N Engl J Med. 2015 Jul 16;373(3):232-42. https://doi.org/10.1056/nejmoa1501352
Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016 May ; 4(5):411-9. https://doi.org/10.1016/s2213-8587(16)00052-8
Pratley RE, Nauck M, Bailey T,Montanya E, Cuddihy R, ,1860-LIRA-DPP-4 Study Group. Et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26- week,randomised, parallel-group, open-label trial. Lancet. 2010 Apr 24; 375(9724):1447-56. https://doi.org/10.1016/s0140-6736(10)60307-8
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, LEADER Trial Investigators, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28; 375(4): 311-22. https://doi.org/10.1056/nejmoa1603827
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, SUSTAIN-6 Investigators, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375:1834-44. https://doi.org/10.1056/nejmoa1607141
Bauduceau B, Bordier L, Doucet J. Les analogues lents de l’insuline : une aide pour l’insulinothérapie des sujets âgés. Méd Mal Méta. 2014 Jun;8(3):293-8. https://doi.org/10.1016/S1957-2557(14)70803-X
Traitement médicamenteux du diabète de type 2. Recommandation de bonne pratique. Diabetes Metab. 2007; 13(5):1S7-25.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2017 Bernard Bauduceau Et al.
